These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 39291967)

  • 1. Comparable glucagon-stimulated amino acid suppression in individuals with and without hepatic steatosis or steatohepatitis.
    Heebøll S; Wegener G; Grønbæk H; Nielsen S
    Am J Physiol Endocrinol Metab; 2024 Sep; ():. PubMed ID: 39291967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease.
    Kjeldsen SAS; Werge MP; Grandt J; Richter MM; Thing M; Hetland LE; Rashu EB; Jensen AH; Winther-Sørensen M; Kellemann JS; Holst JJ; Junker AE; Serizawa RR; Vyberg M; Gluud LL; Wewer Albrechtsen NJ
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G558-G570. PubMed ID: 39104323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
    Heebøll S; Risikesan J; Ringgaard S; Kumarathas I; Sandahl TD; Grønbæk H; Søndergaard E; Nielsen S
    Diabetes; 2022 Nov; 71(11):2402-2411. PubMed ID: 36001750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis.
    Suppli MP; Bagger JI; Lund A; Demant M; van Hall G; Strandberg C; Kønig MJ; Rigbolt K; Langhoff JL; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2020 Jun; 69(6):1090-1099. PubMed ID: 31974144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLUSENTIC Test and Index.
    Kjeldsen SAS; Richter MM; Jensen NJ; Nilsson MSD; Heinz N; Nybing JD; Linden FH; Høgh-Schmidt E; Boesen MP; Andersen TL; Johannesen HH; Trammell SAJ; Grevengoed TJ; Madsbad S; Vilstrup H; Schiødt FV; Møller A; Rashu EB; Nørgaard K; Schmidt S; Gluud LL; Haugaard SB; Holst JJ; Rungby J; Wewer Albrechtsen NJ
    Diabetes; 2024 Oct; 73(10):1716-1727. PubMed ID: 38976454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence.
    McGlone ER; Bloom SR; Tan TM
    J Endocrinol; 2024 Jun; 261(3):. PubMed ID: 38579751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms.
    Richter MM; Kemp IM; Heebøll S; Winther-Sørensen M; Kjeldsen SAS; Jensen NJ; Nybing JD; Linden FH; Høgh-Schmidt E; Boesen MP; Madsbad S; Schiødt FV; Nørgaard K; Schmidt S; Gluud LL; Haugaard SB; Holst JJ; Nielsen S; Rungby J; Wewer Albrechtsen NJ
    Metabolism; 2024 Jul; 156():155915. PubMed ID: 38631460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies.
    Salvoza N; Giraudi P; Gazzin S; Bonazza D; Palmisano S; de Manzini N; Zanconati F; Raseni A; Sirianni F; Tiribelli C; Rosso N
    J Transl Med; 2023 Dec; 21(1):906. PubMed ID: 38082368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study.
    Zyśk B; Ostrowska L; Smarkusz-Zarzecka J; Orywal K; Mroczko B; Cwalina U
    Nutrients; 2024 May; 16(9):. PubMed ID: 38732626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.
    Sandireddy R; Sakthivel S; Gupta P; Behari J; Tripathi M; Singh BK
    Front Cell Dev Biol; 2024; 12():1433857. PubMed ID: 39086662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.
    Bril F; Kalavalapalli S; Lomonaco R; Frye R; Godinez Leiva E; Cusi K
    JHEP Rep; 2024 Jul; 6(7):101092. PubMed ID: 39022386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.
    Winther-Sørensen M; Galsgaard KD; Santos A; Trammell SAJ; Sulek K; Kuhre RE; Pedersen J; Andersen DB; Hassing AS; Dall M; Treebak JT; Gillum MP; Torekov SS; Windeløv JA; Hunt JE; Kjeldsen SAS; Jepsen SL; Vasilopoulou CG; Knop FK; Ørskov C; Werge MP; Bisgaard HC; Eriksen PL; Vilstrup H; Gluud LL; Holst JJ; Wewer Albrechtsen NJ
    Mol Metab; 2020 Dec; 42():101080. PubMed ID: 32937194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.
    Castellano-Castillo D; Núñez-Sánchez MÁ; Balaguer-Román A; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez CM; Frutos MD; Queipo-Ortuño MI; Cardona F; Ramos-Molina B
    Surg Obes Relat Dis; 2024 Jul; 20(7):652-659. PubMed ID: 38490825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.
    Jacobs AK; Morley SD; Samuel K; Morgan K; Boswell L; Kendall TJ; Dorward DA; Fallowfield JA; Hayes PC; Plevris JN
    World J Gastroenterol; 2024 Aug; 30(31):3705-3716. PubMed ID: 39192998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.